《Table 6Lung function tests of four H7N9-induced ARDS patients in experimental group during further

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《间充质干细胞治疗人感染H7N9禽流感病毒所致急性呼吸窘迫综合征的临床研究——为新冠病毒肺炎救治提供新策略》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

Some common side effects still require attention before MSC application can be part of clinical medicine.Although MSC transplantation shows numerous promising results，long-term safety remains a matter of debate，especially since it is diffcult to manage long-term follow-up for all patients[51].The other concern is that MSC not only has the potential to inhibit tumor immune responses，but also can generate new blood vessels，which may promote tumor growth and metastasis[52].Although MSC has shown great promise in the treatment of some immunological diseases （especially graft-versus-host disease (GVHD）)，the variabilities of MSC quality from different donors and tissues are wide，and treatment protocols，doses，and injection modes are inconsistent during experimental procedures[53].All these factors may limit the therapeutic effect of MSCs in clinical application.To overcome these obstacles，careful evaluation of appropriate cell sources，more scientific data，and a more comprehensive and systematic understanding of MSCs immunosuppression are needed.